Drug delivery from ocular implants
Drug delivery from ocular implants
复制标题
DOI：
10.1517/17425247.3.2.261
复制
发表时间：
2006-02
影响因子：
6.6
通讯作者：
T. Yasukawa;Y. Ogura;H. Kimura;E. Sakurai;Y. Tabata
中科院分区：
文献类型：
--
作者：
T. Yasukawa;Y. Ogura;H. Kimura;E. Sakurai;Y. Tabata
开发眼内药物递送系统（DDS）是迫切需要的，因为大多数玻璃体视网膜疾病是难治性的常规药理学方法;滴眼液和全身给药的药物不能提供治疗药物浓度到玻璃体视网膜组织。眼内DDS解决了这个问题。眼内缓释药物通过植入装置或注射微粒已被研究，以治疗玻璃体视网膜疾病。1996年，非生物降解植入物首次用于继发于获得性免疫缺陷综合征的巨细胞病毒视网膜炎。已经研究了由亲水性或疏水性聚合物组成的杆、塞、盘或片形状的生物可降解植入物。一种可注射棒目前正在III期临床试验中进行评估，以治疗继发于糖尿病视网膜病变或视网膜分支静脉阻塞的黄斑水肿。使用生物可降解植入物的眼内DDS可能很快成功地用于治疗严重的眼内疾病。
Developing an intraocular drug delivery system (DDS) is urgently needed because most vitreoretinal diseases are refractory to conventional pharmacological approaches; eye drops and systemically administered drugs cannot deliver therapeutic drug concentrations into vitreoretinal tissue. Intraocular DDSs address this problem. Intraocular sustained-drug release via implantable devices or injectable microparticles has been investigated to treat vitreoretinal diseases. A nonbiodegradable implant was first used in 1996 for cytomegalovirus retinitis secondary to the acquired immunodeficiency syndrome. Biodegradable implants, composed of hydrophilic or hydrophobic polymers, in the shape of rods, plugs, discs or sheets have been investigated. An injectable rod is presently being assessed in a Phase III trial to treat macular oedema secondary to diabetic retinopathy or branch-retinal vein occlusion. Intraocular DDSs using a biodegradable implant may soon be successfully used to treat serious intraocular disorders.